Privium Fund Management B.V. Has $892,000 Stock Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)

Privium Fund Management B.V. boosted its position in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 4.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 213,960 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. Privium Fund Management B.V. owned 0.33% of MeiraGTx worth $892,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in shares of MeiraGTx during the first quarter worth $25,000. China Universal Asset Management Co. Ltd. lifted its holdings in MeiraGTx by 97.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,886 shares of the company’s stock worth $62,000 after acquiring an additional 7,330 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in MeiraGTx by 19.0% in the second quarter. The Manufacturers Life Insurance Company now owns 17,763 shares of the company’s stock valued at $75,000 after acquiring an additional 2,839 shares during the period. SG Americas Securities LLC bought a new stake in shares of MeiraGTx in the third quarter worth about $82,000. Finally, Panagora Asset Management Inc. bought a new stake in shares of MeiraGTx in the second quarter worth about $97,000. Institutional investors own 67.48% of the company’s stock.

Insider Activity at MeiraGTx

In other MeiraGTx news, Director Perceptive Advisors Llc acquired 1,250,000 shares of MeiraGTx stock in a transaction dated Monday, August 12th. The stock was bought at an average cost of $4.00 per share, for a total transaction of $5,000,000.00. Following the purchase, the director now directly owns 12,531,103 shares in the company, valued at approximately $50,124,412. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 8.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on MGTX shares. Chardan Capital reiterated a “buy” rating and issued a $36.00 price objective on shares of MeiraGTx in a research report on Wednesday, July 31st. Royal Bank of Canada reduced their price target on shares of MeiraGTx from $11.00 to $9.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th.

MeiraGTx Stock Up 2.8 %

MGTX stock opened at $6.92 on Friday. The company has a debt-to-equity ratio of 1.04, a current ratio of 2.36 and a quick ratio of 2.36. The stock has a market capitalization of $449.10 million, a P/E ratio of -4.94 and a beta of 1.24. MeiraGTx Holdings plc has a fifty-two week low of $3.85 and a fifty-two week high of $7.60. The business has a 50-day moving average of $4.85 and a 200-day moving average of $4.73.

MeiraGTx (NASDAQ:MGTX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.45). MeiraGTx had a negative return on equity of 152.82% and a negative net margin of 1,146.81%. The firm had revenue of $0.28 million for the quarter, compared to analyst estimates of $16.38 million. On average, sell-side analysts anticipate that MeiraGTx Holdings plc will post -1.37 earnings per share for the current fiscal year.

MeiraGTx Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.